Thomas Eichmann

Dr. Thomas Eichmann


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Cell Metabolism
Verified
Journal Article
Open access
RZRudolf Zechner
Rudolf Zechner
RZRobert Zimmermann
Robert Zimmermann
TEThomas Eichmann
Thomas Eichmann
SKSepp D. Kohlwein
Sepp D. Kohlwein
GHGuenter Haemmerle
Guenter Haemmerle
FMFrank Madeo
Frank Madeo
Lipolysis is defined as the catabolism of triacylglycerols stored in cellular lipid droplets. Recent discoveries of essential lipolytic enzymes and characterization of numerous regulatory proteins and mechanisms have fundamentally changed our perception of lipolysis and its impact on cellular metabolism. New findings that lipolytic products and intermediates participate in cellular signaling processes and that “lipolytic signaling” is particularly important in many nonadipose tissues unveil a previously underappreciated aspect of lipolysis, which may be relevant for human disease.

21 August 2011 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
GHGuenter Haemmerle
Guenter Haemmerle
TMTarek Moustafa
Tarek Moustafa
GWGerald Woelkart
Gerald Woelkart
SBSabrina Büttner
Sabrina Büttner
ASAlbrecht Schmidt
Albrecht Schmidt
RZRudolf Zechner
Rudolf Zechner

25 January 2016 in Nature Communications
Verified
Journal Article
Open access
SRSandro Roier
Sandro Roier
FZFranz Zingl
Franz Zingl
FCFatih Cakar
Fatih Cakar
SDSanel Durakovic
Sanel Durakovic
PKPaul Kohl
Paul Kohl
SSStefan Schild
Stefan Schild
Bacterial outer membrane vesicles (OMVs) have important biological roles in pathogenesis and intercellular interactions, but a general mechanism of OMV formation is lacking. Here we show that the VacJ/Yrb ABC (ATP-binding cassette) transport system, a proposed phospholipid transporter, is involved in OMV formation. Deletion or repression of VacJ/Yrb increases OMV production in two distantly related Gram-negative bacteria, Haemophilus influenzae and Vibrio cholerae. Lipidome analyses demonstrate that OMVs from VacJ/Yrb-defective mutants in H. influenzae are enriched in phospholipids and certain fatty acids. Furthermore, we demonstrate that OMV production and regulation of the VacJ/Yrb ABC transport system respond to iron starvation. Our results suggest a new general mechanism of OMV biogenesis based on phospholipid accumulation in the outer leaflet of the outer membrane. This mechanism is highly conserved among Gram-negative bacteria, provides a means for regulation, can account for OMV formation under all growth conditions, and might have important pathophysiological roles in vivo.

8 July 2015 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
TEThomas Eichmann
Thomas Eichmann
ALAchim Lass
Achim Lass
The neutral lipids diacylglycerols (DAGs) are involved in a plethora of metabolic pathways. They function as components of cellular membranes, as building blocks for glycero(phospho)lipids, and as lipid second messengers. Considering their central role in multiple metabolic processes and signaling pathways, cellular DAG levels require a tight regulation to ensure a constant and controlled availability. Interestingly, DAG species are versatile in their chemical structure. Besides the different fatty acid species esterified to the glycerol backbone, DAGs can occur in three different stereo/regioisoforms, each with unique biological properties. Recent scientific advances have revealed that DAG metabolizing enzymes generate and distinguish different DAG isoforms, and that only one DAG isoform holds signaling properties. Herein, we review the current knowledge of DAG stereochemistry and their impact on cellular metabolism and signaling. Further, we describe intracellular DAG turnover and its stereochemistry in a 3-pool model to illustrate the spatial and stereochemical separation and hereby the diversity of cellular DAG metabolism.

1 August 2009 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
MSMartina Schweiger
Martina Schweiger
ALAchim Lass
Achim Lass
RZRobert Zimmermann
Robert Zimmermann
TEThomas Eichmann
Thomas Eichmann
RZRudolf Zechner
Rudolf Zechner
Neutral lipid storage disease (NLSD) is a group of autosomal recessive disorders characterized by the excessive accumulation of neutral lipids in multiple tissues. Recently, two genes, adipose triglyceride lipase ( ATGL/ PNPLA2) and comparative gene identification-58 ( CGI-58/ABHD5), have been shown to cause NLSD. ATGL specifically hydrolyzes the first fatty acid from triacylglycerols (TG) and CGI-58/ABHD5 stimulates ATGL activity by a currently unknown mechanism. Mutations in both the ATGL and the CGI-58 genes are associated with systemic TG accumulation, yet the resulting clinical manifestations are not identical. Patients with defective ATGL function suffer from more severe myopathy (NLSDM) than patients with defective CGI-58 function. On the other hand, CGI-58 mutations are always associated with ichthyosis (NLSDI), which was not observed in patients with defective ATGL function. These observations indicate an ATGL-independent function of CGI-58. This review summarizes recent findings with the goal of relating structural variants of ATGL and CGI-58 to functional consequences in lipid metabolism.

6 October 2013 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
NMNicole Mayer
Nicole Mayer
MSMartina Schweiger
Martina Schweiger
MRMatthias Romauch
Matthias Romauch
GGGernot F Grabner
Gernot F Grabner
TEThomas Eichmann
Thomas Eichmann
RBRolf Breinbauer
Rolf Breinbauer
A competitive inhibitor of the lipase ATGL reduces the availability of adipocyte fatty acids, causing insulin resistance in insulin-sensitive tissues. Adipose triglyceride lipase (ATGL) is rate limiting in the mobilization of fatty acids from cellular triglyceride stores. This central role in lipolysis marks ATGL as an interesting pharmacological target as deregulated fatty acid metabolism is closely linked to dyslipidemic and metabolic disorders. Here we report on the development and characterization of a small-molecule inhibitor of ATGL. Atglistatin is selective for ATGL and reduces fatty acid mobilization in vitro and in vivo.